Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5KBDY)

Drug Name

PF-06263507 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Preclinical Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Oncotrophoblast glycoprotein 5T4 (TPBG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TroVax	DMHDNK0	Prostate cancer	2C82.0	Phase 3	[3]
Naptumomab estafenatox	DM901ZW	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[4]
CV-9201	DMCPZYT	Non-small-cell lung cancer	2C25.Y	Phase 1/2	[5]
GEN1044	DMQ9317	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
IM1240	DMTV0DK	Aggressive cancer	2A00-2F9Z	Preclinical	[7]
Anatumomab mafenatox	DMMLDG8	Breast cancer	2C60-2C65	Terminated	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Oncotrophoblast glycoprotein 5T4 (TPBG)	TT70MLA	TPBG_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01891669) A Study Of PF-06263507 In Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
2	National Cancer Institute Drug Dictionary (drug id 751006).
3	Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res. 2010 Nov 15;16(22):5539-47.
4	Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin. Curr Oncol Rep. 2014 Feb;16(2):370.
5	National Cancer Institute Drug Dictionary (drug id 648549).
6	Clinical pipeline report, company report or official report of AbbVie.
7	Clinical pipeline report, company report or official report of Purple
8	A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma. Br J Cancer. 2007 Feb 26;96(4):567-74.